Bausch & Lomb, the global eye health company, has entered into a licensing agreement with Santen Pharmaceutical, a developer of ophthalmic and anti-rheumatic pharmaceuticals, for the development of certain intraocular lens materials.
Under the terms of the agreement, Bausch & Lomb has obtained the rights to Santen’s hydrophobic acrylic polymers, from which it may commercialize new intraocular lens for sale worldwide. Santen reserves the right for the use of these materials in the Japanese market. Financial terms will not be disclosed.
John Sheets, Jr, chief technology officer of Bausch & Lomb, said: Bausch & Lomb is enthusiastic about the potential that these polymers hold for developing next-generation intraocular lens, to benefit patients and surgeons alike. Combining these materials with our current product and technology portfolio will provide Bausch & Lomb with an unsurpassed breadth of product offerings.
Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese market.
Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for people around the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals.